Takashi Toya
YOU?
Author Swipe
View article: Molecular basis of potent antiviral HLA-C-restricted CD8+ T cell response to an immunodominant SARS-CoV-2 nucleocapsid epitope
Molecular basis of potent antiviral HLA-C-restricted CD8+ T cell response to an immunodominant SARS-CoV-2 nucleocapsid epitope Open
View article: Machine Learning Algorithm to Explore Patients With Heterogeneous Treatment Effects of Clinically Significant CMV Infection and Non‐Relapse Mortality After HSCT
Machine Learning Algorithm to Explore Patients With Heterogeneous Treatment Effects of Clinically Significant CMV Infection and Non‐Relapse Mortality After HSCT Open
Introduction Clinically significant cytomegalovirus infection (csCMVi) and non‐relapse mortality (NRM) remain serious concerns after allogeneic hematopoietic stem cell transplantation (HSCT), but subpopulations with heterogeneous treatment…
View article: Ponatinib/blinatumomab for relapsed Philadelphia chromosome-positive leukemia as a bridge to allogeneic transplantation
Ponatinib/blinatumomab for relapsed Philadelphia chromosome-positive leukemia as a bridge to allogeneic transplantation Open
We report three cases of ponatinib/blinatumomab (Pona/BLIN) combination therapy as a bridge to allogeneic hematopoietic cell transplantation (allo-HCT) in patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblast…
View article: PRC2‐mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7
PRC2‐mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7 Open
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) harboring both inv(3)/t(3;3) and monosomy 7 (−7) are highly aggressive myeloid cancers of which molecular pathogenesis and therapeutic vulnerability remain elusive. High thro…
View article: Impact of DTaP-IPV and DTaP Vaccination Among Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Prospective Observational Study
Impact of DTaP-IPV and DTaP Vaccination Among Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Prospective Observational Study Open
Background/Objectives: Hematopoietic stem cell transplantation (HSCT) can potentially cure hematological malignancies; however, post-transplant patients have a high risk of infection owing to their immunocompromised status. Vaccination aga…
View article: IMPROVING CELLULAR THERAPY OPERATIONS THROUGH PRE-HARVEST MEASUREMENT OF PERIPHERAL CD34-POSITIVE CELL COUNTS IN ALLOGENEIC STEM CELL HARVEST
IMPROVING CELLULAR THERAPY OPERATIONS THROUGH PRE-HARVEST MEASUREMENT OF PERIPHERAL CD34-POSITIVE CELL COUNTS IN ALLOGENEIC STEM CELL HARVEST Open
View article: Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience
Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience Open
Introduction Donor lymphocyte infusion (DLI) is a therapeutic approach for relapse after hematopoietic stem cell transplantation (HSCT). Despite their reported efficacy, the evolution of DLI practices over time remains underexplored. Metho…
View article: Telomere shortening in donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation: a case report
Telomere shortening in donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation: a case report Open
Donor cell leukemia (DCL), in which malignancy evolves from donor's stem cells, is an infrequent complication of allogeneic hematopoietic stem cell transplantation. Acute promyelocytic leukemia (APL) derived from donor cell is extremely ra…
View article: Improving cellular therapy operations through pre‐harvest measurement of peripheral <scp>CD34</scp>‐positive cell counts in allogeneic stem cell harvest
Improving cellular therapy operations through pre‐harvest measurement of peripheral <span>CD34</span>‐positive cell counts in allogeneic stem cell harvest Open
Introduction Previously, our institution measured peripheral blood CD34 cell counts both pre‐ and post‐peripheral blood stem cell harvest (PBSCH), with both samples analyzed simultaneously post‐PBSCH. Since 2021, we have measured pre‐CD34 …
View article: Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma
Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma Open
Primary vitreoretinal lymphoma (PVRL) is a rare malignant lymphoma subtype with an unfavorable prognosis due to frequent central nervous system (CNS) progression. Thus, identifying factors associated with CNS progression is essential for i…
View article: Case report: Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria
Case report: Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria Open
Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disease characterized by intravascular hemolysis, thrombosis, and bone marrow (BM) failure. Although PNH is caused by excessive proliferation of hematopoietic s…
View article: Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy
Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy Open
Patients with refractory or relapsed (R/R) large B-cell lymphoma (LBCL) refractory to first-line chemotherapy or with early relapse have poor outcomes. While chimeric antigen receptor (CAR) T-cell therapy has impressive efficacy after two …
View article: Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis
Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis Open
Clinically significant cytomegalovirus infection (csCMVi) is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT) and prophylaxis with letermovir is commonly adopted. However, the clinical benefit of letermov…
View article: Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies
Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies Open
Disease recurrence remains the principal cause of treatment failure after allogeneic hematopoietic stem cell transplantation. Post-transplant maintenance therapy with azacitidine (AZA) is promising to prevent relapse but the outcomes are u…
View article: Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria
Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria Open
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disease characterized by intravascular hemolysis, thrombosis, and bone marrow (BM) failure. Although PNH is caused by excessive proliferation of hematopoietic ste…
View article: Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study
Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study Open
Objective The prognosis of patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) is poor. Although patients who fail first‐line salvage chemotherapy are candidates for second‐line salvage chemotherapy, the optima…
View article: Identification of compounds that preferentially suppress the growth of T‐cell acute lymphoblastic leukemia‐derived cells
Identification of compounds that preferentially suppress the growth of T‐cell acute lymphoblastic leukemia‐derived cells Open
T‐cell acute lymphoblastic leukemia (T‐ALL) is one of the most frequently occurring cancers in children and is associated with a poor prognosis. Here, we performed large‐scale screening of natural compound libraries to identify potential d…
View article: Clinical impact and early prediction of carbapenem-resistant Pseudomonas aeruginosa bacteraemia in allogeneic hematopoietic stem cell transplantation recipients
Clinical impact and early prediction of carbapenem-resistant Pseudomonas aeruginosa bacteraemia in allogeneic hematopoietic stem cell transplantation recipients Open
Empirical combination therapy with reference to antimicrobial susceptibility profiles in each institution should be considered when CR P. aeruginosa bacteraemia is suspected in allo-HSCT recipients based on the risk of carbapenem exposure.
View article: Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes
Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes Open
Young adults with myelodysplastic syndrome (MDS) are rare, and the clinical significance of driver mutations has not yet been analysed. We analysed the gene mutations and copy number alterations (CNAs) in younger MDS patients using next-ge…
View article: Mutational analysis of <i>DNMT3A</i> improves the prognostic stratification of patients with acute myeloid leukemia
Mutational analysis of <i>DNMT3A</i> improves the prognostic stratification of patients with acute myeloid leukemia Open
Nucleophosmin1 ( NPM1 ) mutations are the most frequently detected gene mutations in acute myeloid leukemia (AML) and are considered a favorable prognostic factor. We retrospectively analyzed the prognosis of 605 Japanese patients with de …
View article: A third dose of COVID‐19 mRNA vaccine induces limited humoral response in stem cell transplant recipients who got two vaccine doses before transplant
A third dose of COVID‐19 mRNA vaccine induces limited humoral response in stem cell transplant recipients who got two vaccine doses before transplant Open
Allogeneic hematopoietic stem cell transplantation (HSCT) recipients are at high risk of severe coronavirus disease 19 (COVID-19) [1, 2], and sufficient times of vaccinations are strongly recommended. In general, post-HSCT patients should …
View article: Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study
Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study Open
IMRT-TBI is safe and feasible for haematological malignancies with acceptable clinical outcomes.KEY MESSAGESIMRT-TBI-helical tomotherapy aids in accurate dose calculation and conformity.It could be used without any considerable increase in…
View article: Phase I trial of myeloablative conditioning with 3‐day total marrow and lymphoid irradiation for leukemia
Phase I trial of myeloablative conditioning with 3‐day total marrow and lymphoid irradiation for leukemia Open
This prospective phase I trial aimed to determine the recommended dose of 3‐day total marrow and lymphoid irradiation (TMLI) for a myeloablative conditioning regimen by increasing the dose per fraction. The primary end‐point of this single…
View article: Attenuated humoral response against <scp>SARS‐CoV</scp>‐2 <scp>mRNA</scp> vaccination in allogeneic stem cell transplantation recipients
Attenuated humoral response against <span>SARS‐CoV</span>‐2 <span>mRNA</span> vaccination in allogeneic stem cell transplantation recipients Open
Antibody persistence several months after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) mRNA vaccination in allogeneic stem cell transplantation recipients remains largely unknown. We sequentially evaluated the humoral respo…
View article: Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation
Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation Open
Hereditary myeloid malignancies, especially in adults or elderly persons, had been considered quite rare before the next-generation sequencing era; however, increased usage of clinical sequencing has revealed much higher prevalence of inhe…
View article: Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation
Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation Open
Late-onset noninfectious pulmonary complications (LONIPC) are a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). However, the clinical impact of lung function deterioration itself in l…
View article: Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI
Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI Open
The medium‐dose etoposide (VP16) added on cyclophosphamide (CY)/total body irradiation (TBI) is one of the intensified myeloablative conditioning regimens used in allogenic hematopoietic stem cell transplantation (allo‐HSCT) for acute lymp…
View article: Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study
Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study Open
Intensity-modulated radiation therapy (IMRT) helps achieve good radiation dose conformity and precise dose evaluation. We conducted a single-centre prospective study to assess the safety and feasibility of total body irradiation with IMRT …
View article: Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma
Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma Open
Rationale: Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk associated with immune effector cell-associated neurotoxicity sy…
View article: Mutation profiles of diffuse large B‐cell lymphoma transformation of splenic B‐cell lymphoma/leukemia, unclassifiable on whole‐exome sequencing
Mutation profiles of diffuse large B‐cell lymphoma transformation of splenic B‐cell lymphoma/leukemia, unclassifiable on whole‐exome sequencing Open
A 58‐year‐old male was diagnosed with splenic B‐cell lymphoma/leukemia, unclassifiable (SPLL‐U). The lymphoma transformed into diffuse large B‐cell lymphoma (DLBCL), and multidrug chemotherapy and autologous stem cell transplantation achie…